Results 111 to 120 of about 2,106 (155)
Efficacy and safety analysis of different treatment schemes of erythropoiesis-stimulating agents for chronic kidney disease with anemia: a meta analysis between 2000-2024. [PDF]
BMC NephrolOu R +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical Journal of Oncology Nursing, 2003
Darbepoetin alfa, novel erythropoiesis stimulating protein closely related to human erythropoietin, has been developed for the treatment of chemotherapy-related anaemia in patients with non-myeloid malignancies. In three 12-week, phase II studies in patients with cancer and chemotherapy-related anaemia, subcutaneous darbepoetin alfa, administered in ...
Renita Vance, Kathy Wilkinson
+8 more sources
Darbepoetin alfa, novel erythropoiesis stimulating protein closely related to human erythropoietin, has been developed for the treatment of chemotherapy-related anaemia in patients with non-myeloid malignancies. In three 12-week, phase II studies in patients with cancer and chemotherapy-related anaemia, subcutaneous darbepoetin alfa, administered in ...
Renita Vance, Kathy Wilkinson
+8 more sources
Drugs, 2001
Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for the treatment of anaemia associated with chronic kidney disease. In single-dose studies in patients undergoing dialysis, the mean terminal half-life for intravenous darbepoetin alfa was approximately 3-fold longer than for intravenous recombinant human erythropoitin (r-HuEPO ...
T, Ibbotson, K L, Goa
+9 more sources
Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for the treatment of anaemia associated with chronic kidney disease. In single-dose studies in patients undergoing dialysis, the mean terminal half-life for intravenous darbepoetin alfa was approximately 3-fold longer than for intravenous recombinant human erythropoitin (r-HuEPO ...
T, Ibbotson, K L, Goa
+9 more sources
Hospital Pharmacy, 2002
Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +3 more sources
Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +3 more sources
Clinical and economic comparison of epoetin alfa and darbepoetin alfa
Current Medical Research and Opinion, 2004The pharmacoeconomics of erythropoietic therapy for the treatment of anemia is receiving renewed attention due to the current availability of two agents. Epoetin alfa has been the standard of therapy for patients with renal disease and cancer-related anemia for more than a decade.
Anthony, Morreale +4 more
openaire +2 more sources
Darbepoetin Alfa in Systolic Heart Failure
New England Journal of Medicine, 20131. Health homes for enrollees with chronic conditions. Document 10-024. Baltimore: Center for Medicare and Medicaid Services, November 16, 2010 (http://downloads.cms.gov/cmsgov/ archived-downloads/SMDL/downloads/SMD10024.pdf). 2. Primary and behavioral health integration grants.
Dimitrios, Farmakis +2 more
openaire +5 more sources